Understanding such antibody affinity maturation is a key
part of vaccine development.
Not exact matches
The research, published in the September issue
of Immunity, is
part of a broad reverse - engineering effort by scientists around the world to use antibodies isolated from HIV - infected people to guide the
development of a successful
vaccine.
WRAIR is working on the
vaccine in collaboration with other U.S. government agencies, including the NIAID,
part of the National Institutes
of Health, and the Biomedical Advanced Research and
Development Authority,
part of the Department
of Health and Human Services.
MedImmune, a Maryland company, created the live attenuated candidate H7N9
vaccine as
part of a cooperative research and
development agreement with NIAID.
Despite remarkable gains in the treatment and prevention
of HIV infection,
development of an effective HIV
vaccine likely will be necessary to achieve a durable end to the HIV / AIDS pandemic, according to a new commentary from Anthony S. Fauci, M.D., director
of the National Institute
of Allergy and Infectious Diseases (NIAID),
part of the National Institutes
of Health.
Part of this response was for
development of vaccines for potential use in control, a potential facilitated by the rapid identification
of the causative agent, a new coronavirus [8]--[9].
Farokhzad and colleagues have considerable expertise with bench - to - bedside translation
of nanotechnologies for medical applications, and foundational work done in
part by his team has led to the
development and first in human testing
of a targeted nanoparticle capable
of controlling drug release for treatment
of cancers, and the first in human testing
of a targeted nanoparticle
vaccine capable
of orchestrating an immune response to facilitate smoking cessation and relapse prevention.
The Biomedical Advanced Research and
Development Authority (BARDA), part of the Department of Health and Human Services, is exploring advanced development options for the vaccine
Development Authority (BARDA),
part of the Department
of Health and Human Services, is exploring advanced
development options for the vaccine
development options for the
vaccine candidate.
The lab is currently a
part of a multi-institutional group working on developing a prophylactic HIV
vaccine under a five year Integrated Preclinical / Clinical AIDS Vaccine Development Program grant from the National Institutes of Allergy and Infectious Disease (
vaccine under a five year Integrated Preclinical / Clinical AIDS
Vaccine Development Program grant from the National Institutes of Allergy and Infectious Disease (
Vaccine Development Program grant from the National Institutes
of Allergy and Infectious Disease (NIAID).